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Abstract: Ranibizumab, a humanized antigen-binding fragment (Fab) that binds all isoforms 
of VEGF-A, signiﬁ  cantly slows down loss of vision and causes signiﬁ  cant visual improvement 
in many patients with choroidal neovascularization (CNV) due to exudative age-related macu-
lar degeneration (AMD). These beneﬁ  ts of intravitreal ranibizumab apply to all angiographic 
subtypes of neovascular AMD and across all lesion sizes when the drug is injected at monthly 
intervals as shown in two pivotal phase III trials (ANCHOR and MARINA). The results from the 
PrONTO study suggest that less frequent treatment with ranibizumab through a variable dosing 
regimen dependent on optical coherence tomography (OCT) ﬁ  ndings is a treatment option that 
results in comparably favorable visual outcomes. Currently, it is unclear whether combination 
therapy of ranibizumab with photodynamic therapy (PDT) provides any signiﬁ  cant advantage 
over ranibizumab monotherapy (FOCUS trial); however, the combination of PDT and ranibi-
zumab may decrease the need for frequent retreatment. This question will be addressed in the 
SUMMIT trial. Therapy with ranibizumab is generally very well tolerated with a low rate of seri-
ously adverse ocular events or systemic side-effects. The advent of vascular endothelial growth 
factor (VEGF) inhibitors has revolutionized the therapy of neovascular AMD. Ranibizumab at 
the moment appears to be the most effective approved treatment for neovascular AMD.
Keywords: Lucentis, ranibizumab, vascular endothelial growth factor (VEGF), age-related 
macular degeneration (AMD), neovascular, exudative AMD, treatment
Introduction
Age-related macular degeneration (AMD) is the most prevalent cause of moderate and 
severe vision loss in most developed countries. AMD is characterized by irreversible 
damage to the macula resulting in progressive loss of central vision. Two forms of 
AMD exist: non-exudative or non-neovascular (“dry”) AMD, the most common form, 
and exudative or neovascular (“wet”) AMD, which is characterized by the develop-
ment of choroidal neovascularization (CNV). CNV can be subdivided into classic and 
occult forms according to its appearance on ﬂ  ourescein angiography. Both classic and 
occult components can occur within the same lesion. In predominantly classic lesions 
the disease progression is usually more rapid than in the predominantly occult forms. 
Although the neovascular forms of AMD account for only about 10% of the cases, 
they are responsible for 90% of blindness caused by the disease because the presence 
of CNV leads to vascular leakage and subretinal scar formation (Klein et al 1983; 
Green et al 1986).
The role of vascular endothelial growth factor 
(VEGF) in neovascular AMD
Vascular endothelial growth factor (VEGF) is a crucial regulator of vascular permeability 
and angiogenesis (Senger et al 1983; Leung et al 1989). Apart from its physiological 
functions it has a decisive role in tumour-angiogenesis and in the pathogenesis of Clinical Ophthalmology 2008:2(1) 2
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neovascular eye diseases, including neovascular AMD, 
diabetic retinopathy, and retinopathy of prematurity (Adamis 
et al 1994; Pierce et al 1996; Rakic et al 2003). VEGF 
encompasses a group of proteins: VEGF-A, B, C, D, and 
placental growth factor, among which VEGF-A is the most 
relevant for angiogenesis and vascular permeability.
To date, 9 VEGF-A isoforms have been identified: 
VEGF121, VEGF145, VEGF148, VEGF165, VEGF165b, VEGF183, 
VEGF189, and VEGF206. VEGF165 is the isoform that is 
expressed most abundantly (Takahashi et al 2005; Pieramici 
et al 2006). However, VEGF121, VEGF183, and VEGF189 are 
also very frequently encountered in various tissues (Lei et al 
1998; Ferrara et al 2003).
In animal models the inhibition of VEGF-A prevents the 
development of CNV, causes regression of existing CNV, 
reduces pathological vascular permeability and prevents the 
development of iris neovascularization due to retinal ischemia 
(Adamis et al 1996; Krzystolik et al 2002; Akiyama et al 
2005). In humans VEGF-A levels are increased in the vitreous 
of patients with neovascular AMD as well as in excised CNV 
membranes (Wells et al 1996; Grossniklaus et al 2002).
Pharmacology of ranibizumab
Ranibizumab (Lucentis®, Genentech, Inc., San Francisco, 
CA, USA) is a humanized antigen-binding fragment (Fab) 
that neutralizes all VEGF-A isoforms. Ranibizumab was 
developed on the hypothesis that a full-size monoclonal 
antibody against VEGF-A, such as bevacizumab (Avastin®; 
Genentech, Inc., San Francisco, CA, USA), might not pen-
etrate through the retina after intravitreal injection (Presta 
et al 1997). However, recently it has been demonstrated that 
the full-length antibody bevacizumab also penetrates the rab-
bit retina (Shahar et al 2006; Heiduschka et al 2007).
Ranibizumab (molecular weight 48 kDa) and bevaci-
zumab (150 kDA) were derived from the murine monoclo-
nal antibody A4.6.1. Ranibizumab was developed from a 
humanized Fab variant of A4.6.1, known as MB1.6. This Fab 
then underwent a series of modiﬁ  cations: Afﬁ  nity selection 
using phage display technology increased the afﬁ  nity of 
ranibizumab for VEGF-A by several times. Thus, ranibi-
zumab cannot simply be described as a Fab of bevacizumab 
because their complementarity-determining regions (CDR) 
are markedly different (Muller et al 1998; Chen et al 1999). 
In contrast to a full-size antibody, ranibizumab cannot bind 
complement because it lacks the Fc (Fragment crystalliz-
able) region. This may prevent the promotion of intraocular 
inﬂ  ammation after intravitreal injection (Gaudreault et al 
2005; Ferrara et al 2006).
The increased potency, the smaller molecular size 
compared to a full-length antibody for enhanced penetration 
into the retina and choroid, and the lack of the Fc region were 
considered to be advantageous for intravitreal efﬁ  cacy. The 
systemic half-life of ranibizumab is a few hours compared 
to roughly 3 weeks for bevacizumab.
In the vitreous of monkeys the half-life of ranibizumab 
after a single intraocular injection is about 3 days and serum 
levels are very low, approximately 1000-fold lower than 
levels in the eye (Gaudreault et al 2005). The half-life after 
an intraocular injection of a full-length antibody, eg, trastu-
zumab, which is comparable to bevacizumab, is about 6 days 
(Mordenti et al 1999).
Established therapies for 
neovascular AMD prior to the 
introduction of ranibizumab
Laser photocoagulation
Laser photocoagulation was the ﬁ  rst relevant treatment 
introduced to try to halt the progression of neovascular 
AMD. Photocoagulation remains an important treatment 
option for neovascular AMD patients with well-deﬁ  ned 
extrafoveal CNV.
The main beneﬁ  t of the procedure has been described for 
the ﬁ  rst 18 months after the treatment, with 24% of patients in 
the treatment group experiencing a visual loss of more than 6 
lines compared with 41% in the observation group (Macular 
photocoagulation study group 1991). However, in the long 
term almost half of the patients treated will experience recur-
rence with development of subfoveal CNV and subsequent 
visual loss. Furthermore, only a small group of patients 
with neovascular AMD presents with extrafoveal CNV that 
is accessible by laser therapy (Zarbin et al 2007). With the 
advent of photodynamic therapy (PDT) and (later) modern 
pharmacological therapies, and concern for the impact of 
iatrogenic scotoma in subfoveal CNV, laser photocoagula-
tion of peri- and subfoveal CNV is no longer recommended 
(Virgili et al 2000).
Photodynamic therapy
The concept of photodynamic therapy (PDT) is based on the 
high concentration of low-density lipoprotein (LDL) recep-
tors in choroidal neovascular tissue. Verteporﬁ  n (VisudyneTM, 
Novartis, Basel, Switzerland) when infused intravenously 
complexes with LDLs and thus accumulates in CNV mem-
branes. Non-thermal laser activation (689 nm) of verteporﬁ  n 
induces endothelial damage with thrombus formation via Clinical Ophthalmology 2008:2(1) 3
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reactive oxygen species formation without damage to the 
overlying retina (Fingar et al 1996; Zarbin et al 2007).
PDT is effective in reducing the rate of visual loss in 
patients with subfoveal predominantly classic CNV due to 
AMD. In these patients the mean loss of visual acuity after 2 
years was 2.3 lines versus 4.5 lines in the neovascular AMD 
patients treated with placebo (Bressler et al 2002). The aver-
age patient requires 5–6 sessions during the ﬁ  rst 2 years of 
treatment. PDT treatment encompasses a risk of up to 5% 
of visual loss of 4 or more lines within 7 days of treatment 
(Bressler et al 2005).
The efﬁ  cacy in patients with occult or minimal-classic 
type lesion is questionable. Recently, the VIO study failed to 
show any beneﬁ  cial effect of PDT in patients with subfoveal 
occult CNV.
Thus, PDT only had some moderate effect in delaying 
visual loss in a subgroup of patients with neovascular AMD 
(Wormald et al 2005). The off-label use of intravitreal tri-
amcinolone in combination with PDT yielded slightly better 
results (Arias et al 2006) or reduced the number of necessary 
repeat PDT treatments (Ergun et al 2006). However, this 
therapy is hampered by its side-effects – mostly steroid-
induced glaucoma and cataract development.
Surgery for neovascular AMD
Because the formation of choroidal neovascular tissue is the 
hallmark of neovascular AMD, subretinal removal of CNV 
by pars plana vitrectomy has been proposed as a treatment 
modality. The Submacular Surgery Trial (SST), a prospective, 
randomized, multicenter clinical trial, evaluated submacular 
CNV excision versus laser photocoagulation for exudative 
and hemorrhagic subfoveal CNV due to AMD. However, 
CNV removal by submacular surgery was not superior to the 
less invasive laser photocoagulation of subfoveal CNV and 
thus this approach was abandoned with the advent of PDT 
(Bressler et al 2000).
The poor outcome of CNV excision was attributed to 
collateral damage to the retinal pigment epithelium (RPE), 
which is essential for the nutritional supply of the overlying 
macula. To avoid this problem it was suggested to com-
bine CNV extraction with rotation of the macula to areas 
of undamaged RPE. This procedure was named macular 
translocation and is either performed as limited (LMT) or 
full macular translocation (FMT). In LMT the rotation is 
achieved by scleral folding whereas in FMT the retina is 
translocated after performing a 360° retinotomy. As demon-
strated in several case series, LMT and FMT were able to 
prevent visual loss in many patients with neovascular AMD. 
Some patients even experienced a considerable increase 
of visual acuity (Aisenbrey et al 2002; Fujii et al 2002; 
Mruthyunjaya et al 2004). In one prospective, randomized 
mono-center trial FMT was compared with PDT in patients 
with subfoveal classic CNV due to AMD. In this study both 
FMT and PDT prevented visual loss of more than 3 Early 
Treatment Diabetic Retinopathy Study (ETDRS) lines in the 
same percentage of patients. However, the chance of visual 
improvement was signiﬁ  cantly higher in the FMT group 
(Gelisken et al 2007).
Unfortunately, many patients who undergo FMT or LMT 
will complain of diplopia due to the rotated retina sometimes 
even after successful strabismus surgery. In addition, both 
FMT and LMT are complex retinal procedures that are prone 
to surgical complications. Thus, in the era of anti-VEGF 
therapy, macular translocation should not be performed as a 
standard primary procedure for neovascular AMD.
We currently offer FMT only to patients with acute loss 
of vision due to a tear of the RPE that involves the fovea or 
severe subfoveal hemorrhage, and to those who have not 
responded to anti-VEGF therapy, especially if the other eye 
already has end-stage neovascular AMD with subretinal 
scarring.
Other new surgical treatment modalities such as autolo-
gous transplantation of the retinal pigment epithelium and 
choroid are still experimental (MacLaren et al 2007; Heussen 
et al 2007).
Pegaptanib (Macugen®)
Pegaptanib is an oligonucleotide (aptamer) that binds within 
the heparin-binding domain of VEGF-A. It inactivates the 
VEGF165, VEGF189 and VEGF206 isoforms. However, it does 
not bind to other biologically active VEGF-A isoforms such 
as VEGF110, VEGF113, and VEGF121. The VISION trial, a ran-
domized multicenter study, showed that 0.3 mg pegaptanib 
when injected intravitreally every 6 weeks, can reduce the rate 
of visual loss in patients with subfoveal neovascular AMD 
(after 1 year, 70% of the patients treated with pegaptanib 
lost less than three lines versus 55% in the control group) 
(Gragoudas et al 2004).
However, only 5% of the patients treated with pegaptanib 
experienced a moderate improvement of vision. This differ-
ence was not statistically signiﬁ  cant. Thus, pegaptanib did 
not meet the high expectations that were associated with the 
introduction of this ﬁ  rst anti-VEGF agent for neovascular 
AMD. Moreover, about 1% of patients who received the 
medication developed endophthalmitis, and a comparable 
number of patients had other serious ocular side-effects Clinical Ophthalmology 2008:2(1) 4
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including retinal detachments and traumatic cataract 
(Gragoudas et al 2004).
Bevacizumab (Avastin)
Intravenous administration of bevacizumab, a humanized 
full-size antibody that inactivates all isoforms of VEGF-A, 
has been approved for the treatment of metastatic colorectal 
cancer as it has been shown to increase survival time when 
it is added to chemotherapy with 5-ﬂ  uorouracil (Adams et al 
2005; Hurwitz et al 2005).
Off-label systemically administered bevacizumab was 
studied in an uncontrolled open label trial in 18 patients 
with CNV due to AMD. It caused improvement in median 
visual acuity of 14 letters and substantial reduction in foveal 
thickness over a period of 24 weeks. However, in several 
patients there was a signiﬁ  cant elevation in blood pressure 
that required adjustment or initiation of antihypertensive 
medicines (Moshfeghi et al 2006). To avoid these systemic 
complications, intravitreal injection of bevacizumab (the 
most commonly used dose being 1.25 mg) has subse-
quently been proposed and shown to yield similar positive 
results in a number of uncontrolled, mostly retrospective 
studies – with a very low rate of ocular and systemic side-
effects (Rosenfeld et al 2005a; Avery et al 2006; Bashshur 
et al 2006; Costa et al 2006; Rich et al 2006; Spaide et al 
2006; Aisenbrey et al 2007; Chen et al 2007; Emerson et al 
2007; Goff et al 2007; Lazic et al 2007).
Unfortunately, no randomized clinical trials that address 
the efﬁ  cacy of intravitreal bevacizumab in neovascular AMD 
have been performed so far.
Ranibizumab – a breakthrough in 
the treatment of neovascular AMD
Phase III trials – MARINA and ANCHOR
The MARINA study, a randomized, double-blind, controlled, 
multicenter phase III clinical trial, investigated the response 
of neovascular AMD patients with minimally classic or occult 
CNVs to ranibizumab (Rosenfeld et al 2006a). 716 patients 
were randomly assigned to receive 0.3 mg ranibizumab 
(n = 238), 0.5 mg ranibizumab or sham injections at monthly 
intervals for two years (Figure 1). After 24 months 90% of 
the ranibizumab-treated patients had lost fewer than 15 letters 
compared with 53% in the control group. Moreover, 33.3% 
of patients receiving 0.5 mg and 26.1% of patients receiv-
ing 0.3 mg ranibizumab gained at least 15 letters of visual 
acuity versus only 3.8% in the sham-injected patients. After 
2 years, mean visual acuity had increased by 6.6 lines in the 
0.5 mg ranibizumab group versus a decrease of 14.9 lines in 
the sham cohort (Figure 2). This favorable treatment outcome 
was independent of membrane type (minimally classic or 
purely occult CNV), the initial visual acuity or the lesion size. 
Another useful endpoint regarding function is the percent-
age of patients who achieve 20/40 vision or better, because 
that level of vision is sufﬁ  cient for reading reasonably sized 
print. There were no differences among the groups at baseline 
(about 15%), but at 1 year, approximately 40% of patients in 
the ranibizumab groups achieved 20/40 compared to 11% in 
the sham group. Another interesting aspect regarding func-
tion was the percentage of patients that fell to vision 20/200 
or worse which is equivalent to legal blindness in the United 
States. About 12% of patients in the ranibizumab groups had 
visual acuity of 20/200 or worse compared to 43% in the 
sham injection group. Thus, irrespective of different assess-
ments, patients treated with 0.3 or 0.5 mg of ranibizumab did 
substantially better than those who received sham injections. 
The area of CNV lesion showed no change over the course 
of a year in patients treated with ranibizumab in contrast to 
an increase of about 2 disc areas in the control group. This 
indicates that although ranibizumab seems not to cause 
regression of neovascularization, it does seem to stop the 
growth of CNV.
There was a risk of about 1% of developing presumed 
endophthalmitis in the treatment group. (0.00043 per indi-
vidual injection). No statistically signiﬁ  cant increase of 
hypertension or myocardial infarction could be observed. The 
risk of stroke was 0.8% in the sham-treated patients versus 
1.3% (0.3 mg) and 2.5% (0.5 mg) in the ranibizumab-treated 
patients; these differences were not statistically signiﬁ  cant. 
However, since the study was not powered to detect differ-
ences in adverse events, the absence of statistical signiﬁ  cance 
should not be overrated.
Another major randomized, double-blind, controlled, 
multicenter phase III clinical trial, the ANCHOR study, 
assessed the effect of ranibizumab in patients with 
predominantly classic CNVs (Brown et al 2006; Schmidt-
Erfurth et al 2007). 432 patients were randomly assigned to 
receive either PDT with verteporﬁ  n every three months as 
needed plus a monthly sham injection (n = 143) or sham PDT 
as needed every 3 months plus a monthly injection of either 0.3 
mg (n = 140) or 0.5 mg (n = 140) ranibizumab (Figure 3). After 
24-months of follow-up, 90% of both ranibizumab treated 
groups lost less than 15 letters of visual acuity versus 65% in 
the PDT treated group (Figure 4). In the 0.5 mg ranibizumab 
cohort, 41%, and in the 0.3 mg group, 34% gained at least 15 
letters of vision versus 6% in the PDT-treated patients (Figure 
5). Mean visual acuity increased by 11.3 letters in the 0.5 mg Clinical Ophthalmology 2008:2(1) 5
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ranibizumab plus sham PDT group whereas in the verteporﬁ  n 
PDT plus sham injection cohort it decreased by 10.4 letters. 
The risk of presumed endophthalmitis was about 1% among 
the ranibizumab-treated subjects. These results were similar to 
those seen in the MARINA trial and together they show that 
ranibizumab is the ﬁ  rst agent that is able to cause signiﬁ  cant 
visual improvement in a substantial number of patients with 
CNV due to AMD.
Although the studies were not designed to detect differ-
ences between the 0.3 mg and 0.5 mg doses, it was suggested 
that the 0.5 mg dose was superior. Moreover, there was no 
evidence of signiﬁ  cant toxicity with either dose. Thus, 0.5 mg 
was the dose that was ﬁ  nally approved for intravitreal use in 
patients with neovascular AMD.
Patients who completed the ANCHOR or MARINA trial 
were offered the opportunity to participate in the HORIZON 
trial, an open-label extension trial in which re-injections 
of ranibizumab are given as needed. First results show that 
about half of the patients require re-injections within the 
ﬁ  rst 6 months. Because the inhibition of VEGF is a non-
curative approach, it is not foreseeable at any time in the 
future that patients will be able to deﬁ  nitely terminate the 
treatment.
No clinical head-to-head comparison between ranibi-
zumab and pegaptanib, currently the only other anti-VEGF 
agent approved for the treatment of neovascular AMD, has 
been performed so far. However, the gains in mean visual 
acuity with ranibizumab (11.3 letters, ANCHOR 12 months; 
7.2 letters, MARINA 12 months) versus a mean loss with 
pegaptanib (7.5 letters, VISION 12 month) are highly 
suggestive for the superiority of ranibizumab for the treat-
ment of neovascular AMD (Stone et al 2006; Takeda et al 
Figure 1 MARINA trial design.
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2007). However, there are other anti-VEGF medications 
on the horizon that may be even more effective than ranibi-
zumab, eg, VEGF-Trap. Recently, a phase III clinical trial has 
started which will compare the effectiveness of VEGF-Trap 
and ranibizumab (VIEW1).
When adapting the data to real world conditions, the strict 
exclusion criteria of the ANCHOR and MARINA studies 
should be considered in order to avoid overestimation as well as 
an apples and oranges comparison (Rosenfeld et al 2006c): No 
lesions greater than 12 disc areas were included. For the lesion 
composition, the CNV portion within the lesion had to be 50% 
or more of the total lesion size. No subfoveal ﬁ  brosis or atro-
phy was allowed. No pre-treated eyes were considered and no 
concurrent intraocular condition was permitted. Only patients 
with signs of recent disease progression (10% increase in 
lesion size within 1 month, visual acuity loss 1 Snellen line, 
or subretinal hemorrhage 1 disc area) were included.
Despite the improvement in mean visual acuity, a pro-
portion of 59% (ANCHOR) to 76% of patients (MARINA) 
showed no improvement. In this group, the absence of 
a functional increase could be caused either by the pre-
existing damage, eg, irreversible loss of photoreceptors, 
VEGF-independent disease progression, or insufficient 
VEGF-inhibition by ranibizumab.
Might this be a sign of treatment coming too late? 
Strangely, also the area occupied by the CNV in the fel-
low eye seems to inﬂ  uence the severity of AMD changes 
(Abugreen et al 2003). That may support the possibility of a 
patient-speciﬁ  c risk proﬁ  le which corresponds to the lesion 
size. In the ANCHOR and the MARINA trials, in the group 
that lost 15 letters or more, a signiﬁ  cant increase in total 
lesion area after monthly ranibizumab injection was reported. 
As this group also differed from the gainers in initial lesion 
size, but not in the decrease in leakage area, the authors 
postulated an overlaying process of geographic atrophy not 
responsive to ranibizumab (Rosenfeld et al 2006c).
Searching for an optimized strategy for 
re-injection – the PIER and the PRONTO 
studies
In the MARINA and ANCHOR trials, improvement in visual 
acuity appeared to reach a plateau after around 4 months. 
Moreover, monthly intraocular injections entail a certain risk 
and are expensive. These considerations lead to the presump-
tion of two phases: a loading phase, during which 3 doses are 
needed to maximize the initial response, and a maintenance 
phase, in which a less frequent or a ﬂ  exible treatment regimen 
can reduce injection related risks and costs.
A less frequent injection schedule was ﬁ  rst investigated 
in the PIER study (Mieler et al 2006). Patients with subfoveal 
CNV were randomly assigned to receive either 0.5 mg 
ranibizumab (n = 61) or 0.3 mg ranibizumab (n = 60) or 
placebo (n = 63). Enrolled patients received three injections 
with ranibizumab or sham injections every 4 weeks followed 
by re-injections every 3 months. Patients treated with 
ranibizumab showed a mean improvement in visual acuity 
Figure 2 MARINA trial: after 2 years mean visual acuity had increased by 6.6 lines in the ranibizumab 0.5 mg group versus a decrease of 14.9 lines in the sham group. This 
favorable outcome was independent of membrane type (minimally classic or purely occult CNV), the initial visual acuity, or the lesion size. Adapted with permission from 
Rosenfeld PJ, Brown DM, Heier JS, et al. 2006a. Ranibizumab for neovascular age-related macular degeneration. N Eng J Med, 355:1419–31. Copyright © 2006. Massachusetts 
Medical Society.   All rights reserved.
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of 2.9 and 4.8 letters (0.3 and 0.5 mg, respectively) at 
3 months, but after 12 months there was a mean reduction 
of 1.6 and 0.2 letters (0.3 and 0.5 mg, respectively). 
Although ranibizumab-treated patients still had a much 
better outcome than the sham-injected patients, who lost 
on average 16.3 letters, in comparison to the results with 
the monthly regimen that was used in the MARINA and 
ANCHOR trials the outcome was worse.
Comparable to the PIER study is the EXCITE trial in which 
350 patients with classic or occult CNV were assigned to receive 
three injections every 4 weeks followed by re-injections every 3 
months of either ranibizumab 0.3 mg or 0.5 mg . However, the 
results of the EXCITE trial have not been published yet.
The outcomes from the PIER study suggest that a ﬁ  xed 
schedule of injections every 3 months is not an appropriate 
strategy.
However, if a variable re-injection schedule dependent 
on optical coherence tomography (OCT) and other clinical 
changes is used, the outcome seems to be better, as the results 
from a small open-label trial (PRONTO study) suggest (Fung 
et al 2007). In this study 40 patients with subfoveal CNV 
received three monthly injections of 0.5 mg ranibizumab 
and thereafter re-injections only when one of the following 
criteria was fulﬁ  lled: a) increase of central retinal thickness 
of 100 μm or more, b) loss of at least 5 letter of visual acuity, 
c) persistence of sub- or intraretinal ﬂ  uid 1 month after the 
Figure 3 ANCHOR trial design.
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Figure 5 In patients with classic subfoveal CNV due to AMD, ranibizumab improved vision signiﬁ  cantly in up to 41% of patients (12-month results modiﬁ  ed according to 
Brown et al 2006; 24-month results according to Schmidt-Erfurth et al 2007).
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Figure 4 In patients with classic subfoveal CNV due to AMD, ranibizumab prevented visual loss in a signiﬁ  cantly higher number of patients than PDT (12-month results 
modiﬁ  ed according to Brown et al 2006; 24-month results according to Schmidt-Erfurth et al 2007).
ANCHOR
(loss <15 letters) after  1 and 2 years
PDT  (n=143)
1 year 2 years
120
100
80
60
40
20
64% 65%
90.0% 90.0% 94.0% 96.0%
0
Ranibizumab 0.3 mg
(n=140)
Ranibizumab 0.5 mg
(n=139)
%
 
o
f
 
p
a
t
i
e
n
t
sClinical Ophthalmology 2008:2(1) 9
Ranibizumab for age-related macular degeneration
last injection, d) new hemorrhage in the macula, or e) new 
onset classic CNV. OCT was performed at baseline and at 
least monthly after injection. Fluorescein angiograms were 
obtained at baseline and every 3 months thereafter. The mean 
change in visual acuity was an improvement of 9.3 letters, 
95% of the patients lost less than 15 letters, and 35% gained 
at least 15 letters. On average, central retinal thickness 
decreased by 178 μm compared with baseline.
These outcomes are similar to those observed in the 
MARINA and the ANCHOR trial. The mean number of 
injections in the PRONTO study over the ﬁ  rst year was 5.6 
(versus 13 in the MARINA study). The rationale for an OCT 
guided re-injection regimen is also supported by the OCT 
results of the MARINA study in which a close correlation of 
foveal thickness and response to ranibizumab therapy could 
be observed (Kaiser et al 2007).
While one cannot compare the results of a small open-label 
non-randomized trial with those of a large randomized trial, 
it seems likely that monthly injections may not be required 
to achieve optimal results. The safety and efﬁ  cacy of ranibi-
zumab administered on as-needed dosing regimen will 
be assessed in the SUSTAIN study. However, in this non-
randomized, open-label and uncontrolled phase III clinical 
trial, the 0.3 mg dose of ranibizumab will be used, which is 
somehow problematic because 0.5 mg is the approved, and 
possibly more effective dose (www.clinicaltrials.gov/show/
NCT00331864).
Ranibizumab plus PDT
Combining anti-VEGF therapy with other interventions could 
provide further improvement or may decrease the need for 
frequent re-injections. One approach to achieve this goal may 
be combination therapy of ranibizumab with verteporﬁ  n-
PDT since after PDT the production of VEGF is increased 
(Schmidt-Erfurth et al 2003; Tatar et al 2006).
Most patients undergoing PDT have persistent CNV 
perfusion and gradual recanalization of the CNV leading to 
the need for re-treatment can be observed (Schmidt-Erfurth 
et al 2002).
Inactivating VEGF-A by ranibizumab or another 
anti-VEGF agent shortly after or before PDT with verteporﬁ  n 
may stop CNV growth and vascular leakage. Furthermore, 
decreasing CNV perfusion by PDT may decrease the number 
of required ranibizumab injections and thus reduce the 
likelihood of injection-related adverse ocular events. Monkey 
experiments demonstrated that the combination of ranibizumab 
and verteporﬁ  n-PDT reduces leakage from laser-induced 
CNVs more than PDT alone (Hussain et al 2005).
In the FOCUS study, a phase I/II, multicenter, randomized, 
single-masked, controlled study patients with predominantly 
classic CNV were randomly assigned to receive PDT plus 
monthly sham injection (n = 56) or PDT plus monthly 0.5 mg 
ranibizumab ( n = 105). PDT was performed 7 days before 
initial ranibizumab or sham treatment and then quarterly as 
needed according to established criteria (Heier et al 2006a).
Sham and true injections were administered every month 
unless PDT was given, in which case the intravitreal injec-
tion was skipped. At 12 months 90.5% of patients treated 
with ranibizumab and PDT lost less than 15 letters, 23.8% 
gained at least 3 lines (15 letters), and had a mean increase 
of visual acuity of 4.9 letters, compared to 67.9%, 5.4% and 
a mean visual loss of 8.2 letters, respectively, in the cohort 
treated with PDT alone. The percentage of patients receiv-
ing repeat PDT was signiﬁ  cantly less in the group receiving 
ranibizumab. At 24 months, similar results were observed 
with 88% of patients in the combination treatment group 
losing less than 15 letters (versus 75% in the PDT-treated 
group), 25% gaining at least three lines (versus 7% in the 
PDT only group) and a 12.4 letter beneﬁ  t in mean visual 
acuity change from baseline versus patients treated with PDT 
alone (Novartis unpublished data).
The visual acuity and the safety results were not as good as 
those seen in patients with predominantly classic CNV treated 
with ranibizumab alone in the ANCHOR trial. Moreover, 12% 
of patients treated with combination therapy experienced 
severe intraocular inﬂ  ammation. However, one must be 
careful while comparing the more impressive results of the 
ANCHOR trial with those seen in the FOCUS study because 
the inclusion criteria were different: In the FOCUS study 
many patients had already undergone at least one session of 
PDT prior to enrolment in the study, whereas in the ANCHOR 
study previous PDT treatment was an exclusion criteria. In 
addition, the ranibizumab formulation that was used in the 
FOCUS study (lyophilized ranibizumab) was not the same as 
that in the ANCHOR trial (the liquid ranibizumab formulation 
that later received FDA approval). Thus, the increased rate of 
intraocular inﬂ  ammation was likely a result of the formulation 
used. The formulation was switched to liquid ranibizumab 
during the course of the FOCUS which subsequently may 
decrease the rate of intraocular inﬂ  ammation.
In addition, the safety of liquid ranibizumab (0.5 mg) 
in combination with PDT is investigated in the PROTECT 
study. Patients were scheduled to receive liquid formulation 
ranibizumab one hour after PDT administration. Preliminary 
results showed a lower rate of intraocular inﬂ  ammation than 
in the FOCUS study.Clinical Ophthalmology 2008:2(1) 10
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The role of PDT and ranibizumab combination therapy 
will be further assessed in the SUMMIT trial. This trial aims 
to evaluate the efﬁ  cacy and safety of a combination therapy of 
PDT plus ranibizumab 0.5 mg (administered as needed based 
on pre-deﬁ  ned re-treatment criteria) versus ranibizumab 
0.5 mg monotherapy. The SUMMIT trial encompasses 
three trials: The DENALI study, a 2-year phase IIIb trial 
which plans to enrol 300 patients with primary or active 
subfoveal CNV (all lesions) due to AMD in the United States 
and Canada. One arm of DENALI will also investigate the 
efﬁ  cacy of combining ranibizumab with PDT with reduced 
ﬂ  uence. The DENALI study is accompanied by the MONT 
BLANC study in Europe and the EVEREST trial in Asia 
(London New Drug Group, May 2007).
Finally, the notion of combining anti-VEGF medications 
with intravitreal triamcinolone (with or without PDT) and 
other treatments is already being explored by a number of 
investigators. However, if one includes variations in sequence, 
timing, and dose, the myriad possible combinations could 
easily become more confusing than helpful to ophthalmolo-
gists who are trying to select the best therapeutic option for 
their patients (Stone et al 2006).
Tolerability and safety of ranibizumab
The maximum tolerated single dose of lypophilized ranibi-
zumab seems to be 0.5 mg. In a small series of patients 
(n = 27) with subfoveal CNV secondary to AMD, two 
experienced dose-limiting ocular inﬂ  ammation with 1.0 mg 
(Rosenfeld et al 2005b). However, this inﬂ  ammation usually 
is transient and self-limiting. An escalating injection scheme 
with increasing doses seems to be tolerated well, even if the 
dose is steadily increased up to 2.0 mg and injections are 
only 2 weeks apart (Rosenfeld et al 2006b). The approved 
0.5 mg dose seems to be very well tolerated when given 
repeatedly (Heier et al 2006b). Results from the FOCUS and 
the PROTECT trials suggest that the liquid formulation (the 
currently approved formulation) is better tolerated than the 
reconstituted lyophilized formulation that caused uveitis in 
up to 4% of the patients (Heier et al 2006a).
However, 4 out of 5 presumed cases of endophthalmitis 
in the MARINA study were culture negative and there seems 
to be a concentration-dependent increase of intraocular 
inﬂ  ammation.
Thus, a fair number of these cases of presumed endo-
phthalmitis may be sterile and seem to have a good visual 
prognosis.
In addition, strict sterile injection conditions may decrease 
the rate of endophthalmitis well below 1%. We apply the 
same precautions for patients who receive intravitreal 
injection as for those who undergo cataract surgery (eg, using 
sterile gloves, sterile draping, irrigation of the conjunctiva 
with povidone-iodine, and performing the injection in the 
operating room). In the two pivotal phase III clinical trials, 
ranibizumab treatment was associated with a rate of less than 
1.7% of serious adverse ocular events, including presumed 
endophthalmitis, retinal detachment, and uveitis. The endo-
phthalmitis rate in the MARINA trial was 0.4% (0.3 mg) and 
0.8% (0.5 mg) after 12 months, and 0.8% and 1.3% after 24 
months, respectively. In the ANCHOR study endophthalmitis 
occurred at a comparable rate (Pieramici et al 2006).
The frequency of serious non-ocular adverse events was 
comparable for the ranibizumab-treated patients versus the 
sham or PDT-treated cohort in the MARINA, ANCHOR, 
and PIER trials.
The safety of ranibizumab (0.3 and 0.5 mg intravitreally) 
is further investigated in the SAILOR study, an ongoing phase 
IIIb clinical trial. In this study patients are randomly assigned 
to receive either 0.3 mg or 0.5 mg intravitreally every 4 weeks 
for 3 months and then as needed dependent on predeﬁ  ned 
retreatment criteria. Preliminary data from an interim safety 
analysis after 6 months showed a higher incidence of stroke 
in the 0.5 mg group (1.2% versus 0.3% in the 0.3 mg cohort). 
Patients with a history of stroke appeared to be at a higher 
risk of subsequent stroke (Genentech “Dear Health Care 
Provider” letter January 24, 2007).
However, the incidence of stroke in the 0.5 mg cohort 
was still well within the range that can be considered normal 
for the age group of the enrolled patients. But the rate of 
stroke for the 0.3 mg group was below the expected average 
incidence for the enrolled age group, therefore indicating 
less prevalent morbidity.
Further awareness seems necessary before surveillance 
data will allow a conclusive assessment.
Nevertheless, the ﬁ  ndings of the 6-month interim analysis 
led Genentech to issue a letter to healthcare providers in the 
United States regarding the ﬁ  ndings of this planned interim 
analysis. Currently the regulatory authorities in the European 
Union and other countries have not requested such a letter 
to be circulated.
There were no statistically signiﬁ  cant differences between 
the two ranibizumab groups regarding other thromboembolic 
events such as myocardial infarction or vascular death. The 
fact that clinical trials are conducted on a carefully screened, 
relatively small group of patients under highly controlled 
circumstances limits the conclusions for moderately rare 
side-effects and the risks among understudied populations Clinical Ophthalmology 2008:2(1) 11
Ranibizumab for age-related macular degeneration
such as minorities and patients who have multiple health 
problems or chronic illnesses (Olson 2004).
Quality of life and anti-VEGF therapy
Quality-of-life data obtained during the MARINA trial by 
using the National Eye Institute Questionnaire (VFQ-25) 
(Maguire et al 2004) showed signiﬁ  cant improvement in 
VFQ-25 scores in ranibizumab-treated patients (including 
vision speciﬁ  c dependency, near vision, distance vision, 
contrast sensitivity, and global vision – Chang et al 
2007).
Using known disease-speciﬁ  c value-based medicine 
information (time trade-off utility) in patients with 
moderate and advanced neovascular AMD, therapy with 
ranibizumab appears to deliver an extraordinary degree 
of value compared to many other medical interventions 
(Brown et al 2007).
One should keep in mind that patients with moderate 
AMD have quality of life similar to those with moderate 
stroke or AIDS. Very severe AMD (visual acuity below 
20/800 bilaterally) even approaches quality-of-life levels that 
are similar to those encountered with prostate cancer with 
uncontrolled pain or a stroke which leaves a patient bedridden 
and in need of constant care (Brown et al 2007).
Extrafoveal CNV due to AMD
No comparative trial of laser photocoagulation with ranibi-
zumab (or other anti-VEGF agents) for extrafoveal CNV 
due to neovascular AMD has been performed so far. Laser 
photocoagulation remains a useful tool to halt progression 
of extrafoveal CNV.
There may be a rationale for combining laser with 
anti-VEGF therapy in the treatment of extrafoveal CNV due 
to neovascular AMD.
Ranibizumab (Lucentis) versus 
bevacizumab (Avastin)
Bevacizumab is substantially cheaper than ranibizumab 
(Steinbrook 2006; Rosenfeld 2006). A vast number of ret-
rospective case series (Rosenfeld et al 2005a; Avery et al 
2006; Bashshur et al 2006; Costa et al 2006; Rich et al 2006; 
Spaide et al 2006; Aisenbrey et al 2007; Chen et al 2007; 
Emerson et al 2007; Goff et al 2007; Lazic et al 2007) and 
one prospective non-randomized study (Costa et al 2006) 
found intravitreal bevacizumab to be very effective for 
subfoveal CNV due to neovascular AMD.
The intravitreal half-life of bevacizumab in humans is 
likely to be longer than that of ranibizumab (Mordenti et al 
1999; Gaudreault et al 2005). That may be advantageous in 
respect to the number of required re-injections. On the other 
hand, the afﬁ  nity of ranibizumab for VEGF-A is higher than 
that of bevacizumab (Ferrara et al 2006). It is unclear whether 
this has clinical implications. The presence of the Fc fragment 
in bevacizumab might render patients receiving bevacizumab 
more susceptible to the development of an immune response 
to the agent. This may pose the danger that recipients of repeat 
bevacizumab injections experience intraocular inﬂ  ammation 
and that re-injections of the drug are less effective due to 
inactivation of the monoclonal antibody by the immune 
system.
However, these doubts may not be substantiated given the 
good clinical safety, tolerability and efﬁ  cacy that have been 
documented in numerous patients including a database of 
thousands of bevacizumab-treated patients (Fung et al 2006; 
Maturi et al 2006; Michels 2006; Wu et al 2007; Ziemssen 
et al 2007).
In addition there is considerable experimental evidence 
that supports the safety of intravitreal bevacizumab (Luke 
et al 2006; Feiner et al 2006; Spitzer et al 2006; Spitzer et al 
2007). However, this requires conﬁ  rmation in controlled 
clinical trials, which are currently lacking.
Overall it seems likely that intravitreal bevacizumab 
and ranibizumab may have comparable visual beneﬁ  ts 
for patients suffering from neovascular AMD. Still one 
must keep in mind that intravitreal bevacizumab remains 
an off-label therapy that has not been approved by regu-
latory authorities for intraocular use. In addition, to date 
no standardized treatment protocols for re-evaluation and 
re-injection criteria for bevacizumab in neovascular AMD 
have been established.
It is unclear how bevacizumab and ranibizumab compare 
when given by intraocular injection, but a clinical trial 
sponsored by the NIH in the United States that will test 
this issue is underway (Comparison of AMD Treatments 
Trial – CATT).
However, even if a controlled clinical trial showed the 
two drugs to be equivalent, it remains unclear how bevaci-
zumab might be authorized for intraocular use. Thus, even if 
the CATT trial should show the two drugs to be equivalent, 
the dilemma may go on for ophthalmologists who may feel 
pressured to continue using the more expensive but licensed 
alternative (Raftery et al 2007).
Conclusion
The impressive results with ranibizumab are far superior to 
those seen with PDT or pegaptanib. Therefore, monotherapy Clinical Ophthalmology 2008:2(1) 12
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with ranibizumab has become the standard for care of 
patients with new onset of subfoveal CNV due to AMD 
regardless, of type and size of lesion. Ranibizumab can be 
administered either by monthly intravitreal injections or by 
three intraocular injections once a month followed by a re-
injection schedule depending on changes of OCT ﬁ  ndings 
and visual acuity. At this time, it cannot be predicted how 
long repeated intravitreal injections will have to be continued 
after 24 months. It is also unknown how ranibizumab and 
the many times cheaper bevacizumab compare when given 
by intraocular injection. Thus, head-to-head trials that 
assess comparative safety and efﬁ  cacy of ranibizumab and 
bevacizumab are needed.
Currently, it is unclear whether combination therapy of 
ranibizumab with photodynamic therapy (PDT) provides any 
signiﬁ  cant advantage over ranibizumab monotherapy.
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